{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:35:48Z","timestamp":1793522148747,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Taisho Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Arteriosclerosis and non-alcoholic fatty liver disease are major complications of diabetes mellitus. Hyperglycemia, insulin resistance, obesity, and metabolic syndrome are associated with the progression of these complications. Sodium-glucose transporter 2 inhibitors such as luseogliflozin are oral hypoglycemic agents that reduce glucose levels, induce loss of weight or body fat, and improve liver function. However, the effects of these agents on lipid profiles are unclear. Therefore, this study aimed to investigate these effects and their relationship with arteriosclerosis and non-alcoholic fatty liver disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-center, single-arm, open-labeled prospective study enrolled 25 outpatients with type 2 diabetes mellitus who visited Minami Osaka Hospital. Laboratory tests and body measurements were performed at weeks 0 and 24. Luseogliflozin was started at 2.5\u00a0mg\/day after breakfast, and data from weeks 0 and 24 were evaluated. There were no changes in the doses of other antidiabetic and dyslipidemia drugs a month prior to or during the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients showed significant reductions in the levels of triglycerides, remnant-like particle cholesterol, and triglyceride\/high-density lipoprotein cholesterol ratio, along with significant increases in the levels of high-density lipoprotein cholesterol and apolipoprotein A-1. Alanine aminotransferase, \u03b3-glutamyl transpeptidase, and the fatty liver index were significantly reduced.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Luseogliflozin-induced changes in the lipid profile were related to the suppression or improvement of arteriosclerosis and liver function, respectively. Patients who received this drug also showed improvements in the levels of liver enzymes and reductions in the fatty liver index. Earlier use of luseogliflozin might prevent diabetic complications.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> This study was registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN 000043595) on April 6th, 2021<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-023-01074-1","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T02:02:09Z","timestamp":1683770529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Beneficial effects of luseogliflozin on lipid profile and liver function in patients with type 2 diabetes mellitus (BLUE trial): a single-center, single-arm, open-label prospective study"],"prefix":"10.1186","volume":"15","author":[{"given":"Yuriko","family":"Hajika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuro","family":"Kumeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jdi.12645","volume":"8","author":"J Nakamura","year":"2017","unstructured":"Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001\u20132010: report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig. 2017;8:397\u2013410. https:\/\/doi.org\/10.1111\/jdi.12645.","journal-title":"J Diabetes Investig"},{"key":"1074_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ncp.10449","volume":"35","author":"MS Mundi","year":"2020","unstructured":"Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35:72\u201384. https:\/\/doi.org\/10.1002\/ncp.10449.","journal-title":"Nutr Clin Pract"},{"key":"1074_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515\u201331. https:\/\/doi.org\/10.1210\/er.2010-0029.","journal-title":"Endocr Rev"},{"key":"1074_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo11020087","volume":"11","author":"Z Szekeres","year":"2021","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11:87. https:\/\/doi.org\/10.3390\/metabo11020087.","journal-title":"Metabolites"},{"key":"1074_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5152\/EurJTher.2019.19005","volume":"26","author":"E G\u00fcrkan","year":"2020","unstructured":"G\u00fcrkan E. Effects of dapagliflozin on serum LDL-cholesterol and triglyceride levels. Eur J Ther. 2020;26:76\u201380. https:\/\/doi.org\/10.5152\/EurJTher.2019.19005.","journal-title":"Eur J Ther"},{"key":"1074_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12944-017-0443-4","volume":"16","author":"SA Cha","year":"2017","unstructured":"Cha SA, Park YM, Yun JS, Lim TS, Song KH, Yoo KD, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16:58. https:\/\/doi.org\/10.1186\/s12944-017-0443-4.","journal-title":"Lipids Health Dis"},{"key":"1074_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2021.06.915","volume":"330","author":"M Rau","year":"2021","unstructured":"Rau M, Thiele K, Korbinian Hartmann NU, M\u00f6llmann J, Wied S, B\u00f6hm M, et al. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis. 2021;330:8\u201313. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.06.915.","journal-title":"Atherosclerosis"},{"key":"1074_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3349\/ymj.2022.63.7.619","volume":"63","author":"Z Xu","year":"2022","unstructured":"Xu Z, Hu W, Wang B, Xu T, Wang J, Wei D. Canagliflozin ameliorates nonalcoholic fatty liver disease by regulating lipid metabolism and inhibiting inflammation through induction of autophagy. Yonsei Med J. 2022;63:619\u201331. https:\/\/doi.org\/10.3349\/ymj.2022.63.7.619.","journal-title":"Yonsei Med J"},{"key":"1074_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12851","volume":"10","author":"T Sasaki","year":"2019","unstructured":"Sasaki T, Sugawara M, Fukuda M. Sodium\u2013glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the components of weight loss in Japanese patients with type 2 diabetes mellitus) Study. J Diabetes Investig. 2019;10:108\u201317. https:\/\/doi.org\/10.1111\/jdi.12851.","journal-title":"J Diabetes Investig"},{"key":"1074_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cpdd.364","volume":"6","author":"Y Samukawa","year":"2017","unstructured":"Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, et al. Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild\/moderate hepatic impairment: a pharmacokinetic study. Clin Pharmacol Drug Dev. 2017;6:439\u201347. https:\/\/doi.org\/10.1002\/cpdd.364.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/00498254.2016.1193263","volume":"47","author":"A Miyata","year":"2017","unstructured":"Miyata A, Hasegawa M, Hachiuma K, Mori H, Horiuchi N, Mizuno-Yasuhira A, et al. Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, in humans. Xenobiotica. 2017;47:332\u201345. https:\/\/doi.org\/10.1080\/00498254.2016.1193263.","journal-title":"Xenobiotica"},{"key":"1074_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33.","journal-title":"BMC Gastroenterol"},{"key":"1074_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357. https:\/\/doi.org\/10.1002\/hep.29367.","journal-title":"Hepatology"},{"key":"1074_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-230X-12-2","volume":"12","author":"Y Sumida","year":"2012","unstructured":"Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2. https:\/\/doi.org\/10.1186\/1471-230X-12-2.","journal-title":"BMC Gastroenterol"},{"issue":"Suppl 1","key":"1074_CR15","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.amjcard.2019.10.029","volume":"124","author":"JB McGill","year":"2019","unstructured":"McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol. 2019;124(Suppl 1):S45-52. https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.029.","journal-title":"Am J Cardiol"},{"key":"1074_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrd1658","volume":"4","author":"P Linsel-Nitschke","year":"2005","unstructured":"Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193\u2013205. https:\/\/doi.org\/10.1038\/nrd1658.","journal-title":"Nat Rev Drug Discov"},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1194\/jlr.M800196-JLR200","volume":"50","author":"S Nakanishi","year":"2009","unstructured":"Nakanishi S, Vikstedt R, S\u00f6derlund S, Lee-Rueckert M, Hiukka A, Ehnholm C, et al. Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity. J Lipid Res. 2009;50:183\u201392. https:\/\/doi.org\/10.1194\/jlr.M800196-JLR200.","journal-title":"J Lipid Res"},{"key":"1074_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CRD.0000000000000137","volume":"25","author":"VA Eyvazian","year":"2017","unstructured":"Eyvazian VA, Frishman WH. Evacetrapib: another CETP inhibitor for dyslipidemia with no clinical benefit. Cardiol Rev. 2017;25:43\u201352. https:\/\/doi.org\/10.1097\/CRD.0000000000000137.","journal-title":"Cardiol Rev"},{"key":"1074_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.5551\/jat.24315","volume":"21","author":"M Kubota","year":"2014","unstructured":"Kubota M, Nakanishi S, Hirano M, Maeda S, Yoneda M, Awaya T, et al. Relationship between serum cholesterol efflux capacity and glucose intolerance in Japanese-Americans. J Atheroscler Thromb. 2014;21:1087\u201397. https:\/\/doi.org\/10.5551\/jat.24315.","journal-title":"J Atheroscler Thromb"},{"key":"1074_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0021-9150(90)90006-5","volume":"84","author":"L Calabresi","year":"1990","unstructured":"Calabresi L, Franceschini G, Sirtori M, Gianfranceschi G, Werba P, Sirtori CR. Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. Atherosclerosis. 1990;84:41\u20138. https:\/\/doi.org\/10.1016\/0021-9150(90)90006-5.","journal-title":"Atherosclerosis"},{"key":"1074_CR21","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993\u20132000. https:\/\/doi.org\/10.1001\/jama.2009.1619.","journal-title":"JAMA"},{"key":"1074_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jacl.2015.11.017","volume":"10","author":"MH Yang","year":"2016","unstructured":"Yang MH, Sung J, Gwak GY. The associations between apolipoprotein B, A1, and the B\/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016;10:289\u201398. https:\/\/doi.org\/10.1016\/j.jacl.2015.11.017.","journal-title":"J Clin Lipidol"},{"key":"1074_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2119\/molmed.2012.00113","volume":"18","author":"EA Karavia","year":"2012","unstructured":"Karavia EA, Papachristou DJ, Liopeta K, Triantaphyllidou IE, Dimitrakopoulos O, Kypreos KE. Apolipoprotein A-I modulates processes associated with diet-induced nonalcoholic fatty liver disease in mice. Mol Med. 2012;18:901\u201312. https:\/\/doi.org\/10.2119\/molmed.2012.00113.","journal-title":"Mol Med"},{"key":"1074_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1248\/bpb.b15-00716","volume":"39","author":"SY Morita","year":"2016","unstructured":"Morita SY. Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis. Biol Pharm Bull. 2016;39:1\u201324. https:\/\/doi.org\/10.1248\/bpb.b15-00716.","journal-title":"Biol Pharm Bull"},{"key":"1074_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/liv.13363","volume":"37","author":"J Wang","year":"2017","unstructured":"Wang J, Zhu W, Huang S, Xu L, Miao M, Wu C, et al. Serum apoB levels independently predict the development of non-alcoholic fatty liver disease: a 7-year prospective study. Liver Int. 2017;37:1202\u20138. https:\/\/doi.org\/10.1111\/liv.13363.","journal-title":"Liver Int"},{"key":"1074_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(06)69472-5.","journal-title":"Lancet"},{"key":"1074_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11886-011-0220-3","volume":"13","author":"BG Talayero","year":"2011","unstructured":"Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544\u201352. https:\/\/doi.org\/10.1007\/s11886-011-0220-3.","journal-title":"Curr Cardiol Rep"},{"key":"1074_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/jcm7110378","volume":"7","author":"D Pastori","year":"2018","unstructured":"Pastori D, Baratta F, Novo M, Cocomello N, Violi F, Angelico F, et al. Remnant lipoprotein cholesterol and cardiovascular and cerebrovascular events in patients with non-alcoholic fatty liver disease. J Clin Med. 2018;7:378. https:\/\/doi.org\/10.3390\/jcm7110378.","journal-title":"J Clin Med"},{"key":"1074_CR29","first-page":"75","volume":"22","author":"SK Singh","year":"2020","unstructured":"Singh SK, Aggarwal J, Kathariya G, Manzoor S. Usefulness of the TG\/HDL ratio in predicting cardiovascular risk: a MMIMSR experience. JK Sci. 2020;22:75\u20139.","journal-title":"JK Sci"},{"key":"1074_CR30","doi-asserted-by":"publisher","first-page":"504219","DOI":"10.3389\/fneur.2020.504219","volume":"11","author":"MH Woo","year":"2020","unstructured":"Woo MH, Lee KO, Chung D, Choi JW, Kim SH, Oh SH. Triglyceride\/HDL-cholesterol ratio as an index of intracranial atherosclerosis in nonstroke individuals. Front Neurol. 2020;11:504219. https:\/\/doi.org\/10.3389\/fneur.2020.504219.","journal-title":"Front Neurol"},{"key":"1074_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/hepr.13236","volume":"49","author":"Y Sumida","year":"2019","unstructured":"Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (lead trial). Hepatol Res. 2019;49:64\u201371. https:\/\/doi.org\/10.1111\/hepr.13236.","journal-title":"Hepatol Res"},{"key":"1074_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1253\/circj.66.987","volume":"66","author":"Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity","year":"2002","unstructured":"Examination Committee of Criteria for \u201cObesity Disease\u201d in Japan, Japan Society for the Study of Obesity. New criteria for \u2018obesity disease\u2019 in Japan. Circ J. 2002;66:987\u201392. https:\/\/doi.org\/10.1253\/circj.66.987.","journal-title":"Circ J"},{"key":"1074_CR33","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.3390\/nu14173531","volume":"14","author":"S Hata","year":"2022","unstructured":"Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, et al. Gut microbiota changes by an sglt2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db\/db mice. Nutrients. 2022;14:3531. https:\/\/doi.org\/10.3390\/nu14173531.","journal-title":"Nutrients"},{"key":"1074_CR34","doi-asserted-by":"publisher","first-page":"15449","DOI":"10.1038\/s41598-022-19371-6","volume":"12","author":"K Ejiri","year":"2022","unstructured":"Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, et al. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. Sci Rep. 2022;12:15449. https:\/\/doi.org\/10.1038\/s41598-022-19371-6.","journal-title":"Sci Rep"},{"key":"1074_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s42399-020-00707-0","volume":"3","author":"M Kubota","year":"2021","unstructured":"Kubota M, Shiroyama E, Tanaka K, Yoshii Y. Short-term renoprotective effect of SGLT-2 inhibitor for renal function and albuminuria in Type 2 diabetes: a retrospective study. SN Compr Clin Med. 2021;3:201\u20139. https:\/\/doi.org\/10.1007\/s42399-020-00707-0.","journal-title":"SN Compr Clin Med"},{"key":"1074_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","volume":"16","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8. https:\/\/doi.org\/10.1186\/s12933-016-0491-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1074_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/13813455.2016.1195411","volume":"123","author":"AM Kaneva","year":"2017","unstructured":"Kaneva AM, Potolitsyna NN, Bojko ER. Usefulness of the LDL-C\/apoB ratio in the overall evaluation of atherogenicity of lipid profile. Arch Physiol Biochem. 2017;123(1):16\u201322. https:\/\/doi.org\/10.1080\/13813455.2016.1195411.","journal-title":"Arch Physiol Biochem"},{"key":"1074_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12944-017-0417-6","volume":"16","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Koba S, Ito Y, Hirano T. Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels. Lipids Health Dis. 2017;16:21. https:\/\/doi.org\/10.1186\/s12944-017-0417-6.","journal-title":"Lipids Health Dis"},{"key":"1074_CR39","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13300-021-01014-0","volume":"12","author":"H Seino","year":"2021","unstructured":"Seino H. Efficacy and safety of luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, exploratory trial. Diabetes Therapy. 2021;12:863\u201377. https:\/\/doi.org\/10.1007\/s13300-021-01014-0.","journal-title":"Diabetes Therapy"},{"key":"1074_CR40","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1007\/s13300-021-01123-w","volume":"12","author":"H Seino","year":"2021","unstructured":"Seino H. Correction to: efficacy and safety of luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, exploratory trial. Diabetes Ther. 2021;12:2807\u201311. https:\/\/doi.org\/10.1007\/s13300-021-01123-w.","journal-title":"Diabetes Ther"},{"key":"1074_CR41","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/jdi.13237","volume":"11","author":"B Xing","year":"2020","unstructured":"Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W. Effects of sodium\u2013glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Investig. 2020;11:1238\u201347. https:\/\/doi.org\/10.1111\/jdi.13237.","journal-title":"J Diabetes Investig"},{"key":"1074_CR42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022;6:120\u201332.","journal-title":"Hepatol Commun"},{"key":"1074_CR43","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","volume":"8","author":"M Sano","year":"2016","unstructured":"Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8:844\u20137. https:\/\/doi.org\/10.14740\/jocmr2760w.","journal-title":"J Clin Med Res"},{"key":"1074_CR44","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41440-020-0426-0","volume":"43","author":"K Kohagura","year":"2020","unstructured":"Kohagura K, Yamasaki H, Takano H, Ohya Y, Seino Y. Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes. Hypertens Res. 2020;43:876\u201383. https:\/\/doi.org\/10.1038\/s41440-020-0426-0.","journal-title":"Hypertens Res"},{"key":"1074_CR45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clinthera.2015.10.025","volume":"38","author":"M Haneda","year":"2016","unstructured":"Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, et al. Influence of renal function on the 52-week efficacy and safety of the sodium glucose cotransporter 2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2016;38:66-88.e20. https:\/\/doi.org\/10.1016\/j.clinthera.2015.10.025.","journal-title":"Clin Ther"},{"key":"1074_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/hep.22399","volume":"48","author":"JJ Maher","year":"2008","unstructured":"Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48:670\u20138. https:\/\/doi.org\/10.1002\/hep.22399.","journal-title":"Hepatology"},{"key":"1074_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","volume":"205","author":"JC Fruchart","year":"2009","unstructured":"Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205:1\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.03.008.","journal-title":"Atherosclerosis"},{"key":"1074_CR48","doi-asserted-by":"publisher","first-page":"4709300","DOI":"10.1155\/2022\/4709300","volume":"2022","author":"C Chen","year":"2022","unstructured":"Chen C, Li H, Song J, Zhang C, Li M, Mao Y, et al. Role of apolipoprotein A1 in PPAR signaling pathway for nonalcoholic fatty liver disease. PPAR Res. 2022;2022:4709300. https:\/\/doi.org\/10.1155\/2022\/4709300.","journal-title":"PPAR Res"},{"key":"1074_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/s1590-8658(02)80194-3","volume":"34","author":"A Lonardo","year":"2002","unstructured":"Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis. 2002;34:204\u201311. https:\/\/doi.org\/10.1016\/s1590-8658(02)80194-3.","journal-title":"Dig Liver Dis"},{"key":"1074_CR50","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/j.1440-1746.2006.04698.x","volume":"22","author":"PJ Hsiao","year":"2007","unstructured":"Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22:2118\u201323. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04698.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"1074_CR51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13104-020-05059-5","volume":"13","author":"H Tutunchi","year":"2020","unstructured":"Tutunchi H, Saghafi-Asl M, Asghari-Jafarabadi M, Ostadrahimi A. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults. BMC Res Notes. 2020;13:218. https:\/\/doi.org\/10.1186\/s13104-020-05059-5.","journal-title":"BMC Res Notes"},{"key":"1074_CR52","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/gast.2001.25540","volume":"121","author":"JB Dixon","year":"2001","unstructured":"Dixon JB, Bhathal PS, O\u2019Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91\u2013100. https:\/\/doi.org\/10.1053\/gast.2001.25540.","journal-title":"Gastroenterology"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01074-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01074-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T02:03:41Z","timestamp":1683770621000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01074-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01074-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"19 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the approval of the institutional review board of Minami Osaka Hospital (No. 2021-2). This study was conducted in accordance with the tenets of the Declaration of Helsinki. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YH received lecture honoraria from Taisho Co. Ltd. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}